![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NEUROPHARMACOLOGY
Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois
The vanilloid receptor transient receptor potential type V1 (TRPV1) integrates responses to multiple stimuli, such as capsaicin, acid, heat, and endovanilloids and plays an important role in the transmission of inflammatory pain. Here, we report the identification and in vitro characterization of A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel, potent, and selective TRPV1 antagonist. A-425619 was found to potently block capsaicin-evoked increases in intracellular calcium concentrations in HEK293 cells expressing recombinant human TRPV1 receptors (IC50 = 5 nM). A-425619 showed similar potency (IC50 = 3–4 nM) to block TRPV1 receptor activation by anandamide and N-arachidonoyl-dopamine. Electrophysiological experiments showed that A-425619 also potently blocked the activation of native TRPV1 channels in rat dorsal root ganglion neurons (IC50 = 9 nM). When compared with other known TRPV1 antagonists, A-425619 exhibited superior potency in blocking both naive and phorbol estersensitized TRPV1 receptors. Like capsazepine, A-425619 demonstrated competitive antagonism (pA2 = 2.5 nM) of capsaicinevoked calcium flux. Moreover, A-425619 was 25- to 50-fold more potent than capsazepine in blocking TRPV1 activation. A-425619 showed no significant interaction with a wide range of receptors, enzymes, and ion channels, indicating a high degree of selectivity for TRPV1 receptors. These data show that A-425619 is a structurally novel, potent, and selective TRPV1 antagonist.
Address correspondence to: Dr. Rachid El Kouhen, Abbott Laboratories, R4PM, AP9A/2, 100 Abbott Park Road, Abbott Park, IL 60064-6123. E-mail: rachid.elkouhen{at}abbott.com
This article has been cited by other articles:
|
|
 |
|
  A. A. Romanovsky, M. C. Almeida, A. Garami, A. A. Steiner, M. H. Norman, S. F. Morrison, K. Nakamura, J. J. Burmeister, and T. B. Nucci The Transient Receptor Potential Vanilloid-1 Channel in Thermoregulation: A Thermosensor It Is Not Pharmacol. Rev., September 1, 2009; 61(3): 228 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Sappington, T. Sidorova, D. J. Long, and D. J. Calkins TRPV1: Contribution to Retinal Ganglion Cell Apoptosis and Increased Intracellular Ca2+ with Exposure to Hydrostatic Pressure Invest. Ophthalmol. Vis. Sci., February 1, 2009; 50(2): 717 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Surowy, T. R. Neelands, B. R. Bianchi, S. McGaraughty, R. El Kouhen, P. Han, K. L. Chu, H. A. McDonald, M. Vos, W. Niforatos, et al. (R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 879 - 888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Sappington and D. J. Calkins Contribution of TRPV1 to Microglia-Derived IL-6 and NF{kappa}B Translocation with Elevated Hydrostatic Pressure Invest. Ophthalmol. Vis. Sci., July 1, 2008; 49(7): 3004 - 3017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Bianchi, R. El Kouhen, T. R. Neelands, C.-H. Lee, A. Gomtsyan, S. N. Raja, S. N. Vaidyanathan, B. Surber, H. A. McDonald, C. S. Surowy, et al. [3H]A-778317 [1-((R)-5-tert-Butyl-indan-1-yl)-3-isoquinolin-5-yl-urea]: a Novel, Stereoselective, High-Affinity Antagonist Is a Useful Radioligand for the Human Transient Receptor Potential Vanilloid-1 (TRPV1) Receptor J. Pharmacol. Exp. Ther., October 1, 2007; 323(1): 285 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Gunthorpe, S. L. Hannan, D. Smart, J. C. Jerman, S. Arpino, G. D. Smith, S. Brough, J. Wright, J. Egerton, S. C. Lappin, et al. Characterization of SB-705498, a Potent and Selective Vanilloid Receptor-1 (VR1/TRPV1) Antagonist That Inhibits the Capsaicin-, Acid-, and Heat-Mediated Activation of the Receptor J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1183 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Gavva, A. W. Bannon, S. Surapaneni, D. N. Hovland Jr, S. G. Lehto, A. Gore, T. Juan, H. Deng, B. Han, L. Klionsky, et al. The Vanilloid Receptor TRPV1 Is Tonically Activated In Vivo and Involved in Body Temperature Regulation J. Neurosci., March 28, 2007; 27(13): 3366 - 3374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Caterina Transient receptor potential ion channels as participants in thermosensation and thermoregulation Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2007; 292(1): R64 - R76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cui, P. Honore, C. Zhong, D. Gauvin, J. Mikusa, G. Hernandez, P. Chandran, A. Gomtsyan, B. Brown, E. K. Bayburt, et al. TRPV1 Receptors in the CNS Play a Key Role in Broad-Spectrum Analgesia of TRPV1 Antagonists. J. Neurosci., September 13, 2006; 26(37): 9385 - 9393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. McGaraughty, K. L. Chu, C. R. Faltynek, and M. F. Jarvis Systemic and Site-Specific Effects of A-425619, a Selective TRPV1 Receptor Antagonist, on Wide Dynamic Range Neurons in CFA-Treated and Uninjured Rats J Neurophysiol, January 1, 2006; 95(1): 18 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Honore, C. T. Wismer, J. Mikusa, C. Z. Zhu, C. Zhong, D. M. Gauvin, A. Gomtsyan, R. El Kouhen, C.-H. Lee, K. Marsh, et al. A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 410 - 421. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
